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anOBJECTIVES The aim of this study was to prospectively study and conﬁrm the safety and efﬁcacy of the Tryton Side
Branch Stent in the treatment of coronary artery bifurcations involving large side branches (SBs).
BACKGROUND The TRYTON Pivotal randomized controlled trial (RCT) was designed to compare the Tryton stent with
standard provisional SB stenting in large vessels. The trial inadvertently enrolled patients with too small SBs (<2.25 mm).
The overall trial did not meet its primary endpoint, because of an increased rate of periprocedural myocardial infarction in
the Tryton stent arm. A post hoc analysis restricted to the intended population showed that the trial would have met its
endpoint if only patients with SBs $2.25 mm in diameter (by core laboratory quantitative coronary angiography) had
been enrolled.
METHODS The Tryton Conﬁrmatory Study was a prospective, single-arm extension of the TRYTON Pivotal RCT that
enrolled an additional 133 patients treated with the Tryton Side Branch Stent. It was designed to conﬁrm the results of
the post hoc analysis and emphasized the inclusion of appropriately sized SBs. The primary endpoint was noninferiority
with regard to periprocedural myocardial infarction (creatine kinase myocardial band 3 times the upper limit of normal)
compared with a performance goal based on the TRYTON Pivotal RCT.
RESULTS Among the 133 enrolled patients, 132 (99.2%) had SBs $2.25 mm. Baseline clinical and angiographic pa-
rameters were similar in this study and the RCT. Periprocedural myocardial infarction occurred in 10.5% of patients, which
was numerically lower than the provisional group in the TRYTON Pivotal RCT (11.9%). The 95% conﬁdence bounds did
not extend beyond the pre-deﬁned performance goal of 17.9%, meeting the noninferiority primary endpoint.
CONCLUSIONS The Tryton Conﬁrmatory Study, in conjunctionwith the post hoc analysis of the intended population in the
TRYTON Pivotal RCT, supports the safety and efﬁcacy of the Tryton Side Branch Stent for treatment of bifurcation lesions
involving large SBs. (J Am Coll Cardiol Intv 2016;9:1338–46) © 2016 by the American College of Cardiology Foundation.m the aCardiovascular Research Foundation, New York, New York; bNewYork-Presbyterian Hospital/Columbia University
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MB = main branch
PCI = percutaneous coronary
intervention
PPMI = periprocedural
myocardial infarction
QCA = quantitative coronary
angiography
RCT = randomized controlled
trial
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1339B ifurcation lesions are common and representup to 20% of coronary lesions treated withpercutaneous coronary intervention (PCI)
(1,2). Bifurcation PCI is associated with a lower proce-
dural success rate and a higher risk for adverse car-
diac events (1,2). Data from multiple randomized
controlled trials (RCTs) support a provisional 1-stent
strategy over a systematic 2-stent strategy for bifurca-
tion lesions (3–11); however, none of these studies
was restricted to true bifurcation lesions involving
large side branches (SBs).SEE PAGE 1347
side branchThe Tryton Pivotal RCT compared a dedicated
bare-metal stent, designed to speciﬁcally secure and
treat the bifurcation SB, with SB balloon angioplasty
alone (provisional stenting) for the treatment of de
novo true bifurcation lesions (12). The intended study
population was speciﬁed as patients with bifurcations
involving large SBs ($2.5 mm by visual assessment);
however, more than one-half of the enrolled lesions
had diameters <2.25 mm by quantitative coronary
angiography (QCA). This corresponds to a lesion <2.5
mm by visual assessment (12). The trial failed to show
noninferiority to balloon angioplasty alone with re-
gard to its primary endpoint, target vessel failure (a
composite of cardiac death, myocardial infarction,
and target vessel [main vessel or SB] revasculariza-
tion), despite superior angiographic results (lower
diameter stenosis) at 9 months (12). The failure to
meet the primary endpoint was due mainly to an
increased incidence of periprocedural myocardial
infarction (PPMI) in the Tryton stent group. A post
hoc analysis of the intended population restricted to
lesions involving SBs with a reference vessel
diameter $2.25 mm demonstrated superior angio-
graphic results and a numeric reduction in target
vessel failure within the noninferiority margin; how-
ever, because of the nature (retrospective, non-pre-
speciﬁed) of this subanalysis, an additional prospec-
tive study was required to validate these ﬁndings (13).
The Tryton Conﬁrmatory Study was designed in
collaboration with the U.S. Food and Drug Adminis-
tration to: 1) conﬁrm the results seen in the intended
population of the Tryton Pivotal RCT (patients with aAbbott Vascular, Cordis, IDEV, Medtronic, and Volcano. Dr. Laak is a full-t
consultant for Abbott Vascular; and has received speaking fees from Abbott
Cutlip has received research support from Medtronic, Boston Scientiﬁc, and A
of directors of Tryton Medical. Dr. Leon is a member of the scientiﬁc adviso
Medtronic; and is principal investigator of the Tryton Bifurcation Trial. All
lationships relevant to the contents of this paper to disclose.
Manuscript received January 15, 2016; revised manuscript received March 7reference diameter $2.25 mm); and 2) conﬁrm
the ability of physicians to enroll appropriate
patients (with appropriately sized SBs).
METHODS
STUDY POPULATION. Inclusion and exclu-
sion criteria were the same as in the Tryton
Pivotal RCT and have been described in detail
(7). Brieﬂy, patients with symptoms or
objective evidence of ischemia due to a sig-
niﬁcant ($50% narrowing) true bifurcation
lesion (Medina classiﬁcation 1,1,1; 1,0,1; or 0,1,1) (14)
located in a de novo native coronary artery with an
SB 2.5 to 3.5 mm in diameter and a main branch (MB)
2.5 to 4.0 mm in diameter were enrolled. Lesion
length was restricted to #28 mm in the MB (treatable
with a single stent) and #5 mm in the SB. Lesion
evaluation was based on visual estimates of the
baseline angiography. Important exclusion criteria
were 1) ST-segment elevation myocardial infarction
within 72 h or non–ST-segment elevation myocardial
infarction within 7 days preceding the index proce-
dure; 2) left ventricular ejection fraction <30%; 3)
impaired renal function (serum creatinine >2.5 mg/dl
or >221 mmol/l) or current dialysis treatment; 4) left
main coronary artery disease (protected or unpro-
tected); 5) trifurcation lesions; 6) a total occlusion of
the target vessel (MB or SB); 7) severely calciﬁed le-
sion(s); 8) the presence of excessive tortuosity; and 9)
angiographic evidence of thrombus.
STUDY DEVICE AND IMPLANTATION. The Tryton
stent is a dedicated bare-metal cobalt chromium thin-
strutted SB stent mounted on a standard stent de-
livery balloon. The Tryton stent has 3 zones: 1) an SB
zone (5.5 to 6.5 mm) to be deployed within the SB; 2) a
transition zone (4.5 mm) to be positioned at the SB
ostium; and 3) an MB zone (8 mm) (Figure 1).
The implantation technique includes the following
steps: 1) lesion preparation (SB pre-dilation was
mandated and MB pre-dilation was optional); 2)
placement of the Tryton Side Branch Stent in the SB;
3) placement of a commercially available drug-eluting
stent in the MB; and 4) simultaneous ﬁnal kissing
balloon inﬂation. Implantation of an unplanned
SB =ime employee of Tryton Medical. Dr. Bartorelli is a
Vascular, Tryton Medical, and St. Jude Medical. Dr.
bbott Vascular. Dr. Kaplan is a member of the board
ry boards of Abbott Vascular, Boston Scientiﬁc, and
other authors have reported that they have no re-
, 2016, accepted March 24, 2016.
FIGURE 1 The Tryton Side Branch Stent
The Tryton Side Branch Stent is a cobalt chromium, thin-strut, bare-metal stent that is
composed of 3 zones: 1) side branch (SB) zone; 2) transition zone; and 3) main branch (MB)
zone. The SB zone is a conventionally slotted tube for insertion into the SB. The transition
zone is composed of 3 panels that ﬂare and rotate to accommodate a wide spectrum of
bifurcation angle and large variation in SB and proximal MB diameters. When used in
conjunction with a main vessel stent, the Tryton Side Branch Stent is designed to provide
adequate radial strength and coverage across the carina. The MB zone has a minimal metal-
to-artery ratio that is intended as an open path for an MB stent that will lock the Tryton
Side Branch Stent in place. The Tryton stent is mounted on a standard balloon delivery
system; sizes available during the time of the study were (MB/SB) 2.5/2.5 mm, 3.0/2.6 mm,
3.5/2.5 mm, 3.5/3.0 mm, and 4.0/3.5 mm.
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1340additional stent in the SB was allowed in cases of
TIMI (Thrombolysis in Myocardial Infarction) ﬂow
grade <3, vessel dissection type B or worse, or re-
sidual stenosis >80%.
STUDY DESIGN. The Tryton Conﬁrmatory Study was
a prospective single-arm extension of the Tryton
Pivotal RCT that enrolled an additional 133 patients
treated with the Tryton Side Branch Stent and an
approved drug-eluting stent in the MB. The study
mirrored the Tryton Pivotal RCT protocol, which has
previously been described in detail (12). The study
was approved by the Institutional Review Board at
each participating site, and all patients provided
written informed consent.
All serious adverse events were adjudicated by an
independent clinical events committee (Harvard
Cardiovascular Research Institute, Boston, Massa-
chusetts). A data and safety monitoring board had
access to all study data. All data were analyzed by
independent consulting biostatisticians. An inde-
pendent angiographic core laboratory (Cardiovascular
Research Foundation, New York, New York) analyzedall angiograms using a conventional single-vessel al-
gorithm analysis. All patients were required to
receive dual-antiplatelet therapy (unless they devel-
oped contraindications) for 12 months. Clinical
assessment was performed at 30 days and 12 months
post-enrollment. The study emphasized proper SB
selection (i.e., SB reference diameter $2.5 mm by vi-
sual assessment).
STUDY ENDPOINTS. The primary endpoint was PPMI
after PCI, deﬁned as creatine kinase myocardial band
elevation >3 times the upper limit of normal within
48 h after PCI. Patients were compared against a
performance goal derived in close collaboration with
the Food and Drug Administration from the corre-
sponding rate from the angioplasty-only arm (provi-
sional approach) in the intention-to-treat and per
protocol analysis populations in the TRYTON Pivotal
RCT (12,13). Only patients with SBs $2.25 mm by QCA
were included in calculating the performance goal.
This rate was then adjusted upward by 6.0% to allow
for sample variability, resulting in a performance goal
of 17.9% (11.9% þ 6.0%). Noninferiority of the Tryton
Side Branch Stent was deﬁned as a 1-sided 95% con-
ﬁdence bound of the PPMI rate that did not exceed
this performance goal.
Secondary endpoints included the following: all-
cause and cardiac mortality, myocardial infarction,
major adverse cardiac events (a composite of death,
myocardial infarction, emergent bypass surgery, or
target lesion revascularization), target vessel failure
(cardiac death, target vessel myocardial infarction, or
target vessel revascularization), and stent throm-
bosis. Secondary angiographic endpoints included
device success (<30% residual stenosis in the SB) and
lesion success (<50% residual stenosis).
STATISTICAL ANALYSIS. The primary endpoint was
evaluated by the approximate normal method.
Continuous data are presented as mean  SD and
were compared using analysis of variance and the
modiﬁed Student t test or the Kruskal-Wallis test, as
appropriate. Categorical variables were compared
using the chi-square or Fisher exact test. We per-
formed statistical analyses using SAS version 9.1
(SAS Institute, Cary, North Carolina) and considered
p values <0.05 to indicate statistical signiﬁcance.
RESULTS
PATIENTS AND ENROLLMENT. From July 2014 to
July 2015, the Tryton trial enrolled 133 patients from
28 sites (13 in the United States and 15 in Europe).
Of those patients, 132 (99.2%) had SB diameters
$2.25 mm as assessed by QCA. The baseline clinical
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1341characteristics of the patients are presented in Table 1
alongside the patients in the RCT who had SB
diameters $2.25 mm by QCA. No signiﬁcant differ-
ences were present in baseline characteristics, except
for the prevalence of hypertension, which was
signiﬁcantly more common in the Tryton Conﬁrma-
tory Study population compared with the Tryton SB
group (but not the provisional group) of the RCT. In
contrast to the RCT, which enrolled about 10% pa-
tients with non–true bifurcation lesions, all study
patients had true bifurcation lesions (Table 2).
PROCEDURAL AND ANGIOGRAPHIC OUTCOMES.
Among the 133 enrolled patients, 132 (99.2%) received
the study stent in the SB. Procedure, device, and
lesion success rates were signiﬁcantly higher with the
Tryton stent in both the conﬁrmatory study and the
RCT compared with patients who had the provisionalTABLE 1 Baseline Clinical Characteristics
Conﬁrmatory Study RCT
Tryton (n ¼ 133) Tryto
Age, yrs 65.6  9.5 64
Male 93/133 (69.9) 116/
Current smoker 28/133 (21.1) 25/
Diabetes mellitus 34/132 (25.8) 37/
Hypertension 34/132 (82.0) 100/
Hypercholesterolemia 94/132 (71.2) 104
Previous myocardial infarction 43/133 (32.3) 43/
Previous PCI 53/133 (39.8) 54/
Previous CABG 3/133 (2.3) 5/
Previous TIA/CVA 9/133 (6.8) 13/
History of congestive heart failure 8/133 (6.0) 2/
Atrial ﬁbrillation 10/133 (7.5) 18/
Left ventricular ejection fraction, % 56.3  9.5 57
Clinical presentation
Stable angina 98/133 (73.7) 108/
Unstable angina 24/133 (18.0) 28/
Functional test showing ischemia 34/53 (64.2) 50
Access site
Femoral 71/133 (53.4) 94/
Radial 62/133 (46.6) 51/1
Other 0/133 (0.0) 1/1
Number of vessels with $50% stenosis
1 84/133 (63.2) 91/1
2 46/133 (34.6) 47/
3 3/133 (2.3) 8/
Medina classiﬁcation
1,1,1 95/133 (71.4) 95/
1,0,1 15/133 (11.3) 26/
0,1,1 23/133 (17.3) 24/
1,1,0 or 1,0,0 or 0,1,0 or 0,0,1 0/133 (0.0) 1/1
Antiplatelet therapy pre-loading
before index procedure
118/133 (88.7) 127/
Valuesaremean SDorn/N (%). *Tryton group in the conﬁrmatory study versus Tryton grou
CABG ¼ coronary artery bypass graft surgery; CVA ¼ cerebrovascular accident; PCI ¼
branch; TIA ¼ transient ischemic attack.strategy (p < 0.001 for all) (Table 3). The need for
additional stenting in the SB (bailout stenting) was
required in 3 patients (2.3%; 1 dissection, 2 inade-
quate lesion coverage) who received the Tryton stent.
Procedures were on average longer and required more
contrast and radiation when the Tryton stent strategy
was used compared with the provisional 1-stent
strategy (Table 3).
CLINICAL OUTCOMES. Clinical outcomes are sum-
marized in Table 4. No patient died during the pro-
cedure or within 30 days post-procedure. The primary
endpoint, PPMI, occurred in 10.5% of the patients.
This was numerically lower than the provisional
group in the Tryton Pivotal RCT (11.9%) (Figure 2).
The 95% conﬁdence bounds did not extend beyond
the pre-deﬁned performance goal of 17.9%, and the
noninferiority primary endpoint was met.With Side Branch Diameter $2.25 mm
p Value* p Value†n (n ¼ 146) Provisional (n ¼ 143)
.5  10.7 65.2  9.2 0.36 0.72
146 (79.5) 117/143 (81.8) 0.07 0.02
146 (17.1) 22/142 (15.5) 0.40 0.23
146 (25.3) 41/143 (28.7) 0.94 0.79
146 (68.5) 109/142 (76.8) <0.001 <0.001
/144 (72.2) 107/139 (77.0) 0.85 0.47
145 (29.7) 57/141 (40.4) 0.63 0.60
146 (37.0) 62/143 (43.4) 0.62 0.96
145 (3.4) 5/143 (3.5) 0.55 0.50
146 (8.9) 8/143 (5.7) 0.51 0.69
146 (1.4) 0/143 (0.0) 0.04 <0.001
146 (12.3) 12/143 (8.4) 0.18 0.35
.1  9.4 56.8  10.7 0.48 0.68
146 (74.0) 98/143 (68.5) 0.96 0.61
146 (19.2) 34/143 (23.8) 0.81 0.42
/81 (61.7) 46/72 (63.9) 0.78 0.85
146 (64.4) 88/143 (61.5) 0.06 0.06
46 (34.9) 55/143 (38.5) 0.047 0.053
46 (0.7) 1/143 (0.7) 0.34 0.34
46 (64.4) 90/143 (61.5) 0.89 0.92
146 (32.2) 39/143 (27.3) 0.67 0.32
146 (5.5) 14/143 (9.8) 0.17 0.03
146 (65.2) 94/143 (65.7) 0.25 0.22
146 (17.8) 21/143 (14.7) 0.12 0.18
146 (16.4) 27/143 (18.9) 0.85 0.93
46 (0.7) 1/143 (0.7) 0.34 0.34
146 (87.0) 119/143 (83.2) 0.66 0.32
p in the RCT. †Tryton group in the conﬁrmatory study versus provisional group in the RCT.
percutaneous coronary intervention; RCT ¼ randomized controlled trial; SB ¼ side
TABLE 2 Quantitative and Qualitative Angiographic Findings at Baseline and After Procedure
Conﬁrmatory Study RCT With Side Branch Diameter $2.25 mm
p Value† p Value‡Tryton (n ¼ 133) Tryton (n ¼ 146) Provisional (n ¼ 143)
True bifurcation* 133/133 (100) 132/146 (90.4) 132/143 (92.3) <0.001 <0.001
Main branch
Vessel location
Left anterior descending 100/133 (75.2) 104/146 (71.2) 94/143 (65.7) 0.46 0.17
Left circumﬂex 27/133 (21.1) 29/146 (19.9) 36/143 (25.2) 0.93 0.70
Right 5/133 (3.8) 13/146 (8.9) 13/143 (9.1) 0.08 0.07
Baseline
Reference vessel diameter, mm 3.12  0.37 3.09  0.35 3.06  0.34 0.49 0.16
MLD, mm 0.93  0.35 1.12  0.39 1.05  0.38 <0.001 0.007
Diameter stenosis, % 70.21  10.41 63.82  11.96 65.62  11.52 <0.001 <0.001
Lesion length, mm 17.23  7.89 16.14  6.84 16.05  6.53 0.22 0.18
Thrombus 2/133 (1.5) 0/146 (0.0) 2/143 (1.4) 0.23 0.59
Tortuosity
Moderate 6/133 (4.5) 0/146 (0.0) 3/143 (2.1) 0.009 0.02
Severe 1/133 (0.8) 0/146 (0.0) 2/143 (1.4) 0.29 0.95
Calciﬁcation
Moderate 24/133 (18.0) 17/146 (11.6) 22/143 (15.4) 0.13 0.22
Severe 15/133 (11.3) 3/146 (2.1) 5/143 (3.5) 0.002 <0.001
Post-procedure
Reference vessel diameter, mm 3.18  0.44 3.16  0.36 3.11  0.35 0.68 0.15
In-segment MLD, mm 2.42  0.41 2.50  0.35 2.49  0.36 0.08 0.13
In segment diameter stenosis, % 23.74  8.45 20.62  7.29 19.82 7.59 0.001 <0.001
In-stent MLD, mm 2.74  0.39 2.89  0.38 2.82  0.34 0.001 0.07
In-stent diameter stenosis, % 13.50  8.68 20.62  7.29 19.82  7.59 <0.001 <0.001
In-segment acute gain, mm 1.49  0.48 1.38  0.46 1.45  0.44 0.052 0.47
In-stent acute gain, mm 1.81  0.47 1.77  0.46 1.78  0.40 0.47 0.57
Continued on the next page
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Drawn from 133 additional patients, the Tryton
Conﬁrmatory Study conﬁrmed and extended the
ﬁnding of the large SB post hoc analysis of the Tryton
Pivotal RCT. The principal ﬁndings of the Tryton
Conﬁrmatory Study are as follows: 1) among patients
undergoing PCI of true bifurcation lesions with an SB
diameter $2.25 mm, the Tryton 2-stent strategy was
noninferior to the standard 1-stent provisional
approach in terms of PPMI; and 2) appropriate selec-
tion of patients who may beneﬁt from receiving the
Tryton Side Branch Stent is possible.
The intention-to-treat analysis of the Tryton
Pivotal RCT demonstrated that the Tryton Side
Branch Stent was associated with superior angio-
graphic outcomes but failed to meet the pre-speciﬁed
noninferiority criteria (12). The high rate of the com-
posite endpoint, target vessel failure, in the Tryton
group was driven by a higher incidence of PPMI. A
closer look at the data revealed that 59% of the pa-
tients had SBs that were smaller than the pre-
speciﬁed inclusion criteria. These patients had a dis-
proportionally high incidence of procedure-relatedcreatine kinase myocardial band elevation (13). Pa-
tients with too small SBs assigned to the provisional
(control) group were treated with appropriately sized
angiography balloons, whereas those assigned to the
Tryton group were treated with a stent mounted on
an oversized balloon. A post hoc analysis of the
intended study population (i.e., patients with SB
diameters $2.25 mm) instead showed a numeric
reduction in target vessel failure, which was within
the pre-speciﬁed noninferiority margin, and superior
angiographic outcomes at 9 months (13). The present
study, which was designed in collaboration with the
Food and Drug Administration to validate the post
hoc analysis, conﬁrms the safety and efﬁcacy of the
Tryton Side Branch Stent for the treatment of bifur-
cation lesions with SBs $2.25 mm in diameter.
The Tryton Side Branch Stent is the ﬁrst dedicated
bifurcation stent to be compared head to head with the
provisional technique in a multicenter RCT. The Try-
ton Pivotal RCT was also the largest RCT to exclusively
studied bifurcation lesions (12). The pivotal random-
ized trial (12) and its large SB post hoc analysis (13), in
conjunction with the present study, not only demon-
strate the safety and efﬁcacy of the Tryton Side Branch
TABLE 2 Continued
Conﬁrmatory Study RCT With Side Branch Diameter $2.25 mm
p Value† p Value‡Tryton (n ¼ 133) Tryton (n ¼ 146) Provisional (n ¼ 143)
Side branch
Vessel location
Left anterior descending 100/133 (75.2) 106/146 (72.6) 93/143 (65.0) 0.62 0.18
Left circumﬂex 28/133 (21.1) 27/146 (18.5) 37/143 (25.9) 0.59 0.80
Right 5/133 (3.8) 13/146 (8.9) 13/143 (9.1) 0.08 0.055
Baseline
Reference vessel diameter, mm 2.49  0.20 2.53  0.23 2.52  0.22 0.12 0.24
MLD, mm 0.89  0.31 1.06  0.34 1.15  0.35 <0.001 <0.001
Diameter stenosis, % 64.15  12.15 58.13  12.74 54.11  14.34 <0.001 <0.001
Lesion length, mm 5.94  2.53 4.80  1.24 4.60  0.86 <0.001 <0.001
Thrombus 0/133 (0.0) 0/146 (0.0) 0/143 (0.0) — —
Tortuosity
Moderate 12/133 (9.0) 0/146 (0.0) 0/143 (0.0) <0.001 <0.001
Severe 2/133 (1.5) 0/146 (0.0) 2/143 (1.4) 0.14 0.42
Calciﬁcation
Moderate 11/133 (8.3) 7/146 (4.8) 6/143 (4.2) 0.24 0.12
Severe 2/133 (1.5) 1/146 (0.7) 2/143 (1.4) 0.51 0.68
Angulation, 
0–45 109/133 (82.0) 128/146 (87.7) 108/143 (75.5) 0.18 0.94
>45–90 24/133 (18.0) 16/146 (11.0) 32/143 (22.4) 0.09 0.72
>90 0/133 (0.0) 2/146 (1.4) 3/143 (2.1) 0.18 0.13
Post-procedure
Reference vessel diameter, mm 2.55  0.25 2.61  0.26 2.54  0.27 0.050 0.75
In-segment MLD, mm 2.26  0.32 2.33  0.27 1.74  0.48 0.051 <0.001
In segment diameter stenosis, % 11.32  8.44 10.71  6.82 30.89  18.78 0.51 <0.001
In-stent MLD, mm 2.47  0.34 2.59  0.27 — 0.001 —
In-stent diameter stenosis, % 2.98  9.80 0.57  8.24 — 0.028 —
In-segment acute gain, mm 1.37  0.41 1.26  0.36 0.59  0.48 0.02 <0.001
In-stent acute gain, mm 1.58  0.43 1.53  0.36 — 0.30 —
Values are n/N (%) or mean  SD. *Medina classiﬁcation 1,1,1; 1,0,1; or 0,1,1 as per angiographic core laboratory analysis. †Tryton group in the conﬁrmatory study versus Tryton
group in the RCT. ‡Tryton group in the conﬁrmatory study versus provisional group in the RCT.
MLD ¼ minimal lumen diameter; RCT ¼ randomized controlled trial.
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1343Stent but also offer insights regarding what bi-
furcations should be treated with such technology.
Indeed, although provisional stenting should be the
treatment of choice for small SBs (<2.5 mm by visual
assessment) that supply small myocardial territories,
large SBs represent a condition in which acute, short-
term, and midterm patency of an SB could be seen as
extremely important. Indeed, among the 279 patients
with SBs $2.25 mm receiving Tryton stents from both
the Tryton Conﬁrmatory Study and the Tryton Pivotal
RCT, the need for an additional stent in the SB was 4-
fold lower compared with patients undergoing a pro-
visional approach (1.4% vs. 5.6%). Paired with the
superior 9-month angiographic patency (12), these
ﬁndings are extremely important, especially if bifur-
cation stenting is envisioned for even larger SBs, such
as the left main coronary artery.
Procedural, device, and lesion success were
signiﬁcantly higher with the Tryton stent comparedwith the provisional approach. Speciﬁcally, achieve-
ment of ﬁnal diameter stenosis <30% with the
intended initial strategy (w95% for the Tryton stent
vs. w35% for the provisional approach) was superior
in the Tryton group compared with the provisional
arm. In contrast, procedures with the Tryton Side
Branch Stent were longer, with more contrast used
compared with the provisional approach. Actually,
Tryton Side Branch Stent implantation took about 10
minutes more and required about 30 ml more contrast
on average. This ﬁnding is not surprising, considering
that the Tryton Side Branch Stent represents a true
“2-stent” approach, compared with the provisional
strategy, being the simplest “1-stent approach”;
however, when compared with the data from land-
mark studies using a 2-stent approach such as the
Nordic-Baltic Bifurcation Study IV, procedural time,
ﬂuoroscopic time, and amount of contrast were
similar (15). That being said, procedural length and
TABLE 3 Procedural and Device Characteristics
Conﬁrmatory Study RCT With Side Branch Diameter $2.25 mm
p Value§ p ValuekTryton (n ¼ 133) Tryton (n ¼ 146) Provisional (n ¼ 143)
Procedure success* 117/131 (89.3) 125/143 (87.4) 95/142 (66.9) 0.62 0.003
Device success† 122/130 (93.8) 135/143 (94.4) 51/142 (35.9) 0.84 <0.001
Lesion success‡ 133/133 (100) 141/141 (100) 120/142 (84.5) — <0.001
Pre-dilation of the main vessel 124/133 (93.2) 129/144 (89.6) 114/142 (80.3) 0.28 0.02
Pre-dilation of the side branch 131/133 (98.5) 139/146 (95.2) 86/138 (62.3) 0.12 <0.001
Final kissing balloon technique
Attempted 133/133 (100) 134/146 (91.8) 128/143 (89.5) <0.001 <0.001
Not attempted 0/133 (0.0) 7/146 (4.8) 11/143 (7.7) 0.01 0.001
Unsuccessful 9/133 (6.8) 5/146 (3.4) 4/143 (2.8) 0.20 0.12
Tryton stent successfully delivered 132/133 (99.2) 142/146 (97.3) 1/143 (0.7) 0.21 <0.001
2.5/2.5  19 mm 9/132 (6.8) 81/142 (5.6) — <0.001 —
3.0/2.5  19 mm 53/132 (40.2) 40/142 (28.2) — 0.04 —
3.5/2.5  19 mm 36/132 (27.3) 51/142 (35.9) 1/1 (100.0) 0.12 —
3.5/3.0  18 mm 32/132 (24.2) 40/142 (28.2) — 0.46 —
4.0/3.5  18 mm 2/132 (1.5) 3/142 (28.2) — 0.71 —
Additional stent in side branch 3/133 (2.3) 1/146 (0.7) 8/143 (5.6) 0.27 0.76
Nontarget lesion treated 10/133 (7.5) 21/146 (14.4) 23/143 (16.1) 0.07 0.003
Additional nonstudy stent implanted
0 107/133 (80.5) 109/146 (74.7) 100/143 (69.9) 0.25 0.09
1 23/133 (17.3) 29/146 (19.9) 33/143 (23.1) 0.58 0.36
2 2/133 (1.5) 6/146 (4.1) 7/143 (4.9) 0.19 0.16
$3 1/133 (0.8) 2/146 (1.4) 3/143 (2.1) 0.62 0.67
Bare metal stent 2/30 (6.7) 3/47 (6.4) 0/56 (0.0) 0.96 0.34
Drug-eluting stent 28/30 (93.3) 44/47 (93.6) 56/56 (100.0) 0.96 0.34
Adjunctive devices 2/133 (1.5) 3/146 (2.1) 1/143 (0.7) 0.73 0.92
Rotational atherectomy 0/2 (0.0) 0/3 (0.0) 1/1 (100.0) — 0.44
Cutting or AngioSculpt balloon 0/2 (0.0) 0/3 (0.0) 0/1 (0.0) — —
Other 2/2 (100) 3/3 (100.0) 0/1 (0.0) — 0.44
Procedure time, min 64.6  26.2 68.7  30.1 55.9  27.3 0.22 0.007
Fluoroscopic time, min 23.3  11.4 24.0  13.8 11.6  5.4 0.64 <0.001
Contrast volume, ml 248.2  85.6 269.2  98.3 227.0  88.7 0.058 0.044
Values are n/N (%) or mean  SD. *Achievement of ﬁnal in-stent diameter <50% in side branch with assigned study device. †Achievement of ﬁnal in-stent residual
stenosis <30% (by quantitative coronary angiography) in side branch using the assigned study device without malfunction. ‡Achievement of ﬁnal in-stent diameter of <50%
(by quantitative coronary angiography) within the side branch. §Tryton group in the conﬁrmatory study versus Tryton group in the RCT. kTryton group in the conﬁrmatory study
versus provisional group in the RCT.
RCT ¼ randomized controlled trial.
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1344resource use should be weighed against the beneﬁts
of acute and midterm (9-month) SB patency.
The Tryton Pivotal RCT and the subsequent Tryton
Conﬁrmatory Study are studies with a unique design
and scientiﬁc process that illustrate important con-
cepts in RCT planning: 1) the importance of selecting
a clinically appropriate target population; 2) the
importance of enrolling the intended population from
which the scientiﬁc hypothesis was derived; and 3)
the importance of selecting clinically meaningful
endpoints. Similar to our study, many other trials
have initially failed to meet their primary endpoints
(16–18) to subsequently succeed (19,20) after read-
justments of the targeted population or the primary
endpoints, leading to approval for the population in
which the study device or drug was shown to befavorable. However, designing trials on the basis of
subgroup ﬁndings may not always conﬁrm the initial
subgroup results (21,22), illustrating the need and
value for well-conducted, prospective studies to
validate or invalidate subgroup ﬁndings. The Tryton
Conﬁrmatory Study used a unique design, combining
the rigor of a prospective registry with identical in-
clusion and exclusion criteria as the Tryton Pivotal
RCT with the statistical advantages of using a his-
torical cohort as the comparator (i.e., the control
group in the Tryton Pivotal Trial as the performance
goal).
STUDY LIMITATIONS. First, this study was not an
RCT; however, the inclusion and exclusion criteria
were identical to the recently conducted Tryton
TABLE 4 Adverse Events During the Procedure and at 30 Days
Conﬁrmatory Study RCT With Side Branch Diameter $2.25 mm
p Value† p Value‡Tryton (n ¼ 133) Tryton (n ¼ 146) Provisional (n ¼ 143)
Procedure
Myocardial infarction 10.5 (14) 8.2 (12) 11.9 (17) 0.51 0.88
30 days
Target vessel failure* 10.5 (14) 8.2 (12) 11.9 (17) 0.51 0.88
Death 0.0 (0) 0.0 (0) 0.0 (0) — —
Cardiac death 0.0 (0) 0.0 (0) 0.0 (0) — —
Noncardiac death 0.0 (0) 0.0 (0) 0.0 (0) — —
Target vessel myocardial
infarction
10.5 (14) 8.2 (12) 11.9 (17) 0.51 0.88
Q-wave 1.5 (2) 0.7 (1) 0.0 (0) 0.51 0.51
Non-Q-wave 6.8 (9) 7.5 (11) 11.9 (17) 0.80 0.32
Clinically driven TVR 1.5 (2) 0.7 (1) 0.0 (0) 0.51 0.51
ARC-deﬁned stent thrombosis 1.5 (2) 0.7 (1) 0.0 (0) 0.51 0.51
Values are % (n). *Composite of cardiac death, target vessel myocardial infarction, and clinically driven target vessel revascularization; revascularization. †Tryton group in the
conﬁrmatory study versus Tryton group in the RCT. ‡Tryton group in the conﬁrmatory study versus provisional group in the RCT.
ARC ¼ Academic Research Consortium; RCT ¼ randomized clinical trial; TVR ¼ target vessel revascularization.
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1345Pivotal RCT. Therefore, a reliable optimal perfor-
mance goal could be deﬁned (on the basis of
the group that was randomized to the provisional
approach in the RCT). Second, only short lesions (<5
mm) with diameter stenoses >50% were enrolled.
Whether our results can be extrapolated to more
diffuse or physiologically signiﬁcant (as assessed by
fractional ﬂow reserve) SB disease remains to beFIGURE 2 Primary Endpoint: Periprocedural Myocardial
Infarction
Incidence of the pre-speciﬁed primary endpoint, periprocedural
myocardial infarction, in patients enrolled in the Tryton Conﬁr-
matory Study (blue) compared with patients randomized to the
provisional 1-stent control group in the Tryton Pivotal random-
ized controlled trial (RCT) (red). Error bars represent 95% con-
ﬁdence limits, and the dotted red line indicates the pre-deﬁned
performance goal of 17.9%. Noninferiority to this performance
goal was met (p ¼ 0.014).shown. Third, whether the use of the Tryton Side
Branch Stent is cost effective, in light of procedure
time, contrast use, and utilization of other resources
was not addressed in this study. Last, the Tryton Side
Branch Stent is a bare-metal stent. Whether a drug-
eluting version would be superior remains to be
established.CONCLUSIONS
The Tryton Conﬁrmatory Study, assessing the safety
of the Tryton Side Branch Stent in the treatment of
bifurcation lesions involving large SBs, met its pri-
mary endpoint (performance goal) related to PPMI.
This ﬁnding conﬁrms the safety and efﬁcacy of the
Tryton Side Branch Stent in the treatment of bifur-
cation lesions involving a large SB. In light of the
higher procedural success rate, improved acute
angiographic results, and higher rate of SB patency at
9-month follow-up compared with provisional stent-
ing, the Tryton Conﬁrmatory Study and the Tryton
Pivotal RCT support the use of the dedicated Tryton
Side Branch Stent in conjunction with standard drug-
eluting stent in the treatment of bifurcation lesions
involving large SBs.
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PERSPECTIVES
WHAT IS KNOWN? A post hoc analysis of the Tryton
IDE randomized trial restricted to lesions involving large
SBs ($2.25 mm) demonstrated superior angiographic re-
sults and a numeric reduction in target vessel failure
when the dedicated bifurcation Tryton stent was used
compared with a stenting provisional strategy.
WHAT IS NEW? The Tryton conﬁrmatory study pro-
spectively conﬁrmed the safety and efﬁcacy of the
dedicated bifurcation Tryton stent in the treatment of
bifurcation lesion involving large SBs.
WHAT IS NEXT? Future investigation studying a drug-
eluting stent version of the Tryton stent, especially for
left main bifurcation lesion, or use in combination with
bioresorbable vascular scaffold, are needed and could
potentially improve long-term outcomes of such complex
patient population.
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